A citation-based method for searching scientific literature

César Serrano, Yuexiang Wang, Adrián Mariño-Enríquez, Jen-Chieh Lee, Gloria Ravegnini, Jeffrey A Morgan, Monica M Bertagnolli, Carol Beadling, George D Demetri, Christopher L Corless, Michael C Heinrich, Jonathan A Fletcher. J Clin Oncol 2015
Times Cited: 33







List of co-cited articles
269 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
B Liegl, I Kepten, C Le, M Zhu, G D Demetri, M C Heinrich, C D M Fletcher, C L Corless, J A Fletcher. J Pathol 2008
283
63

PDGFRA activating mutations in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Anette Duensing, Laura McGreevey, Chang-Jie Chen, Nora Joseph, Samuel Singer, Diana J Griffith, Andrea Haley, Ajia Town,[...]. Science 2003
60

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
S Hirota, K Isozaki, Y Moriyama, K Hashimoto, T Nishida, S Ishiguro, K Kawano, M Hanada, A Kurata, M Takeda,[...]. Science 1998
57

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
51

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek,[...]. N Engl J Med 2002
51

Gastrointestinal stromal tumours: origin and molecular oncology.
Christopher L Corless, Christine M Barnett, Michael C Heinrich. Nat Rev Cancer 2011
479
48

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
George D Demetri, Peter Reichardt, Yoon-Koo Kang, Jean-Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu,[...]. Lancet 2013
751
42

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Michael C Heinrich, Robert G Maki, Christopher L Corless, Cristina R Antonescu, Amy Harlow, Diana Griffith, Ajia Town, Arin McKinley, Wen-Bin Ou, Jonathan A Fletcher,[...]. J Clin Oncol 2008
491
42

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Charles D Blanke, George D Demetri, Heikki Joensuu, Peter J Roberts, Burton L Eisenberg, Margaret von Mehren, Christopher D M Fletcher, Katrin Sandau,[...]. J Clin Oncol 2006
556
36

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Christopher L Corless, Arin Schroeder, Diana Griffith, Ajia Town, Laura McGreevey, Patina Harrell, Sharon Shiraga, Troy Bainbridge, Jason Morich, Michael C Heinrich. J Clin Oncol 2005
548
36

Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
Leili Ran, Inna Sirota, Zhen Cao, Devan Murphy, Yuedan Chen, Shipra Shukla, Yuanyuan Xie, Michael C Kaufmann, Dong Gao, Sinan Zhu,[...]. Cancer Discov 2015
77
33

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Michael C Heinrich, Christopher L Corless, George D Demetri, Charles D Blanke, Margaret von Mehren, Heikki Joensuu, Laura S McGreevey, Chang-Jie Chen, Annick D Van den Abbeele, Brian J Druker,[...]. J Clin Oncol 2003
33

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Charles D Blanke, George D Demetri, Margaret von Mehren, Michael C Heinrich, Burton Eisenberg, Jonathan A Fletcher, Christopher L Corless, Christopher D M Fletcher, Peter J Roberts, Daniela Heinz,[...]. J Clin Oncol 2008
672
33


ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Ping Chi, Yu Chen, Lei Zhang, Xingyi Guo, John Wongvipat, Tambudzai Shamu, Jonathan A Fletcher, Scott Dewell, Robert G Maki, Deyou Zheng,[...]. Nature 2010
205
27

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Maria Debiec-Rychter, Jan Cools, Herlinde Dumez, Raf Sciot, Michel Stul, Nicole Mentens, Hilde Vranckx, Bartosz Wasag, Hans Prenen, Johannes Roesel,[...]. Gastroenterology 2005
374
27

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Eva Wardelmann, Sabine Merkelbach-Bruse, Katharina Pauls, Nadja Thomas, Hans-Ulrich Schildhaus, Thomas Heinicke, Nicola Speidel, Torsten Pietsch, Reinhard Buettner, Daniel Pink,[...]. Clin Cancer Res 2006
257
27


Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Michael C Heinrich, Diana Griffith, Arin McKinley, Janice Patterson, Ajia Presnell, Abhijit Ramachandran, Maria Debiec-Rychter. Clin Cancer Res 2012
137
24

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Suzanne George, Qian Wang, Michael C Heinrich, Christopher L Corless, Meijun Zhu, James E Butrynski, Jeffrey A Morgan, Andrew J Wagner, Edwin Choy, William D Tap,[...]. J Clin Oncol 2012
170
24

Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.
Heidi M Namløs, Kjetil Boye, Skyler J Mishkin, Tale Barøy, Susanne Lorenz, Bodil Bjerkehagen, Eva W Stratford, Else Munthe, Brian A Kudlow, Ola Myklebost,[...]. Mol Cancer Ther 2018
35
24

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M Mannan, Brian P Rubin, George D Demetri,[...]. Br J Cancer 2019
47
24

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, Anu Gupta, Cynthia B Leary, Scott C Wise, Thomas J Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L Bulfer,[...]. Cancer Cell 2019
65
24

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
Claudia Miranda, Martina Nucifora, Francesca Molinari, Elena Conca, Maria Chiara Anania, Andrea Bordoni, Piercarlo Saletti, Luca Mazzucchelli, Silvana Pilotti, Marco A Pierotti,[...]. Clin Cancer Res 2012
121
21

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Narasimhan P Agaram, Grace C Wong, Tianhua Guo, Robert G Maki, Samuel Singer, Ronald P Dematteo, Peter Besmer, Cristina R Antonescu. Genes Chromosomes Cancer 2008
242
21

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing.
Françoise Ducimetière, Antoine Lurkin, Dominique Ranchère-Vince, Anne-Valérie Decouvelaere, Michel Péoc'h, Luc Istier, Philippe Chalabreysse, Christine Muller, Laurent Alberti, Pierre-Paul Bringuier,[...]. PLoS One 2011
291
21

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
Heikki Joensuu, Aki Vehtari, Jaakko Riihimäki, Toshirou Nishida, Sonja E Steigen, Peter Brabec, Lukas Plank, Bengt Nilsson, Claudia Cirilli, Chiara Braconi,[...]. Lancet Oncol 2012
498
21

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Michael C Heinrich, Kouros Owzar, Christopher L Corless, Donna Hollis, Ernest C Borden, Christopher D M Fletcher, Christopher W Ryan, Margaret von Mehren, Charles D Blanke, Cathryn Rankin,[...]. J Clin Oncol 2008
404
21

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Cristina R Antonescu, Ronald P DeMatteo, Kristen N Ganjoo, Robert G Maki, Peter W T Pisters, Chandrajit P Raut, Richard F Riedel, Scott Schuetze,[...]. J Natl Compr Canc Netw 2010
704
21


Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Jean-Yves Blay, César Serrano, Michael C Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L Jones, Steven Attia, Gina D'Amato,[...]. Lancet Oncol 2020
63
21

FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Fang Li, Hung Huynh, Xiaoyan Li, David A Ruddy, Youzhen Wang, Richard Ong, Pierce Chow, Shumei Qiu, Angela Tam, Daniel P Rakiec,[...]. Cancer Discov 2015
55
18

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Jaap Verweij, Paolo G Casali, John Zalcberg, Axel LeCesne, Peter Reichardt, Jean-Yves Blay, Rolf Issels, Allan van Oosterom, Pancras C W Hogendoorn, Martine Van Glabbeke,[...]. Lancet 2004
18

High incidence of microscopic gastrointestinal stromal tumors in the stomach.
Kaori Kawanowa, Yuji Sakuma, Shinji Sakurai, Tsunekazu Hishima, Yoshiaki Iwasaki, Kana Saito, Yoshinori Hosoya, Takashi Nakajima, Nobuaki Funata. Hum Pathol 2006
234
18

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Sebastian Bauer, Lynn K Yu, George D Demetri, Jonathan A Fletcher. Cancer Res 2006
201
18

Biology of gastrointestinal stromal tumors.
Christopher L Corless, Jonathan A Fletcher, Michael C Heinrich. J Clin Oncol 2004
820
18


Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).
Anette Duensing, Fabiola Medeiros, Bryna McConarty, Nora E Joseph, Dipak Panigrahy, Samuel Singer, Christopher D M Fletcher, George D Demetri, Jonathan A Fletcher. Oncogene 2004
246
18

Dystrophin is a tumor suppressor in human cancers with myogenic programs.
Yuexiang Wang, Adrian Marino-Enriquez, Richard R Bennett, Meijun Zhu, Yiping Shen, Grant Eilers, Jen-Chieh Lee, Joern Henze, Benjamin S Fletcher, Zhizhan Gu,[...]. Nat Genet 2014
94
18

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
César Serrano, Suzanne George, Claudia Valverde, David Olivares, Alfonso García-Valverde, Cristina Suárez, Rafael Morales-Barrera, Joan Carles. Target Oncol 2017
22
27

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
César Serrano, Alessandro Leal, Yanan Kuang, Jeffrey A Morgan, Constance M Barysauskas, Jillian Phallen, Olivia Triplett, Adrián Mariño-Enríquez, Andrew J Wagner, George D Demetri,[...]. Clin Cancer Res 2019
17
35

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap,[...]. Lancet Oncol 2020
62
18

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
Thomas Mühlenberg, Yixiang Zhang, Andrew J Wagner, Florian Grabellus, James Bradner, Georg Taeger, Hauke Lang, Takahiro Taguchi, Martin Schuler, Jonathan A Fletcher,[...]. Cancer Res 2009
62
15

High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors.
Regine Schneider-Stock, Carsten Boltze, Jerzy Lasota, Markku Miettinen, Brigitte Peters, Matthias Pross, Albert Roessner, Thomas Günther. J Clin Oncol 2003
113
15

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Philippe A Cassier, Elena Fumagalli, Piotr Rutkowski, Patrick Schöffski, Martine Van Glabbeke, Maria Debiec-Rychter, Jean-François Emile, Florence Duffaud, Javier Martin-Broto, Bruno Landi,[...]. Clin Cancer Res 2012
101
15

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Andrew P Garner, Joseph M Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzer,[...]. Clin Cancer Res 2014
96
15

Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.
Abbas Agaimy, Peter H Wünsch, Ferdinand Hofstaedter, Hagen Blaszyk, Petra Rümmele, Andreas Gaumann, Wolfgang Dietmaier, Arndt Hartmann. Am J Surg Pathol 2007
237
15

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G Casali,[...]. Eur J Cancer 2006
608
15

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
P Schöffski, P Reichardt, J-Y Blay, H Dumez, J A Morgan, I Ray-Coquard, N Hollaender, A Jappe, G D Demetri. Ann Oncol 2010
84
15

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
Nathalie Javidi-Sharifi, Elie Traer, Jacqueline Martinez, Anu Gupta, Takehiro Taguchi, Jennifer Dunlap, Michael C Heinrich, Christopher L Corless, Brian P Rubin, Brian J Druker,[...]. Cancer Res 2015
59
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.